ALPS Medical Breakthroughs ETF (SBIO)
26.62
+0.12
(+0.46%)
USD |
NYSEARCA |
Mar 24, 16:00
26.47
-0.15
(-0.56%)
After-Hours: 20:00
Key Stats
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.50% | 0.25% | 97.38M | 10865.03 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| 0.00% | 88.00% | -17.02M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | ALPS |
| Prospectus Benchmark Index | |
| S-Network Medical Breakthroughs TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Ryan Mischker | 7.92 yrs |
| Andrew Hicks | 6.92 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
47
-17.02M
-2.719B
Category Low
6.230B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of February 28, 2023
Risk
Performance Versus Category
As of March 24, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of March 24, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Roivant Sciences Ltd Ordinary Shares | 3.67% | 6.92 | -1.00% |
| Prometheus Biosciences Inc | 3.56% | 107.30 | 0.31% |
| Alkermes PLC | 3.04% | 26.49 | 2.87% |
| Cerevel Therapeutics Holdings Inc Ordinary Shares | 2.57% | 23.43 | 0.00% |
| IVERIC bio Inc | 2.32% | 24.17 | 1.94% |
| Zai Lab Ltd ADR Repr 1 Shs | 2.31% | 31.70 | 0.76% |
| Cytokinetics Inc | 2.22% | 33.36 | -0.80% |
| Denali Therapeutics Inc | 2.19% | 22.90 | -0.04% |
| Vaxcyte Inc Ordinary Shares | 2.12% | 37.84 | -0.11% |
| Vir Biotechnology Inc | 2.10% | 22.49 | 1.03% |
News
Headline
Wire
Time (ET)
PR Newswire
06/30 08:51
Basic Info
| Investment Strategy | |
| The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Small Cap/Growth |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | ALPS |
| Prospectus Benchmark Index | |
| S-Network Medical Breakthroughs TR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Ryan Mischker | 7.92 yrs |
| Andrew Hicks | 6.92 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (3-24-23) | 0.00% |
| 30-Day SEC Yield (3-23-23) | Upgrade |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | -- |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of March 24, 2023
Fund Details
| Key Dates | |
| Inception Date | 12/30/2014 |
| Last Annual Report Date | 11/30/2022 |
| Last Prospectus Date | 3/31/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)
PR Newswire
06/30 08:51